Literature DB >> 23040680

Comparison of teicoplanin and vancomycin in vitro activity on clinical isolates of Staphylococcus aureus.

Carlo Tascini1, Sarah Flammini, Alessandro Leonildi, Ilaria Ciullo, Enrico Tagliaferri, Francesco Menichetti.   

Abstract

Ninety-one clinical isolates of Staphylococcus aureus have been tested with the Kirby Bauer and the Etest® method to determine the susceptibility to glycopeptides in the 2007-2010 period. Five strains (5.5%) were resistant to vancomycin and nine (9.9%) to teicoplanin. Teicoplanin showed a median minimal inhibitory concentration (MIC) of 1 mg/l (range 0.125-24 mg/l), an MIC50 of 1 mg/l, and an MIC90 of 2 mg/l; vancomycin had a median MIC of 1.5 mg/l (range 0.38-4 mg/l), an MIC50 of 1.5 mg/l, and an MIC90 of 2 mg/l. More isolates were distributed on higher values of MIC for vancomycin. Inhibition halos induced by vancomycin-impregnated paper diskettes were slightly larger than those by teicoplanin. Glycopeptide resistance among methicillin-resistant Staphylococcus aureus in Italy is an underestimated phenomenon, possibly due to the described underestimation of glycopeptides MICs by the automatic broth microdilution method, when compared to agar MIC assays. A teicoplanin MIC creep, as reported for vancomycin, cannot be assumed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23040680     DOI: 10.1179/1973947812Y.0000000026

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  2 in total

1.  Linezolid in the treatment of severe intraabdominal infection: A STROBE-compliant retrospective study.

Authors:  Deyuan You; Yuexiang Su; Xuri Sun; Jianbao Wang; Yuxin Zheng; Yuqi Liu
Journal:  Medicine (Baltimore)       Date:  2022-08-19       Impact factor: 1.817

2.  Systematic review and meta-analysis of the epidemiology of vancomycin-resistance Staphylococcus aureus isolates.

Authors:  Qianxing Wu; Niloofar Sabokroo; Yujie Wang; Marzieh Hashemian; Somayeh Karamollahi; Ebrahim Kouhsari
Journal:  Antimicrob Resist Infect Control       Date:  2021-06-30       Impact factor: 4.887

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.